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Both parity and a young age at ﬁrst pregnancy are associated with a reduction in breast cancer risk. The hormones involved in
this process are not fully investigated. Human chorionic gonadotropin is a placental hormone, which in rats and in human
breast cells in vitro has been shown to prevent against breast cancer. Hyperemesis, a severe nausea combined with vomiting
during pregnancy, is associated with increased levels of human chorionic gonadotropin. We investigated the possible
relationship between hyperemesis and subsequent breast cancer risk in a case–control study based on registry data. Among
13079 breast cancer cases and 34348 individually matched controls we found 148 cases and 405 controls who had been
hospitalised for hyperemesis. Hyperemesis was not associated with breast cancer risk (adjusted odds ratio 1.05, 95%
conﬁdence interval 0.86–1.27), and similar risks were observed regardless of age at diagnosis, number of hospitalisations for
hyperemesis or time of follow-up. Our results do not support the hypothesis that human chorionic gonadotropin is
responsible for the protective effect of pregnancies upon breast cancer risk.
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The biological mechanisms by which childbearing reduces
breast cancer risk are not fully understood. Human chorionic
gonadotrophin (hCG) is a pregnancy speciﬁc hormone,
produced by trophoblasts. In animal models, hCG has been
shown both to prevent and to inhibit growth of breast cancer
induced by 7,12-dimethylbenz-a-anthrazene (DMBA) (Russo
and Russo, 2000). Likewise, hCG has been shown to inhibit
growth of human breast cancer cells in vitro (Srivastava et
al, 1998). Based on these ﬁndings, hCG has been proposed
as a potential chemopreventive agent against breast cancer,
especially if administered to young, nulliparous women (Rao,
2000).
Observational data on exposure to hCG and subsequent breast
cancer risk are sparse. One study found a signiﬁcant decrease in
breast cancer risk among women who had been administrated
hCG as part of an infertility treatment or as a weight-loss regimen
(Bernstein et al, 1995). On the other hand, two studies found
small increases in risk among women with a previous diagnosis
of hydatidiform moles, a benign placental proliferative disease
linked to elevated levels of hCG (Olsen et al, 1999; Erlandsson
et al, 2000).
Hyperemesis gravidarum, namely nausea combined with persis-
tent vomiting during pregnancy, is linked to increased levels of
hCG compared to normal pregnancies the levels being proportional
to the degree of nausea (Goodwin et al, 1992). Thus, women with a
history of hyperemesis form a suitable group in which to study
effects of exposure to high hCG levels.
We explored the possibility of an association between inpatient
care for hyperemesis gravidarum and the subsequent risk for breast
cancer using Swedish registry data, which also allowed us to adjust
for confounders, such as parity and age at ﬁrst birth.
MATERIALS AND METHODS
Data sources
Data for the present study was obtained from four population-
based registries: the Swedish Cancer Register, the Swedish Regis-
ter of Births, the Swedish In-patient Register, and the Swedish
Medical Birth Register. Information from these registries can
be merged using the unique 10-digit identiﬁcation number
assigned to all Swedish residents at time of birth or ﬁrst resi-
dency.
In the Swedish Cancer Register, information on all incident
cancers in Sweden has been recorded since 1958. Notiﬁcation of
cancer to the Swedish Cancer Register is mandatory both for clin-
icians and pathologists, resulting in an estimated completeness of
over 98% (Mattsson et al, 1985).
The Swedish Register of Births is part of the Swedish population
statistics and has recorded information on all births since 1961,
including sex of the child, multiple births, and area of residence
of the mother.
The Swedish In-Patient Register contains diagnoses and dates of
admission of all hospitalised patients in Sweden. The registry was
established in parts of Sweden in 1964, and the coverage has since
been gradually expanded to include all Sweden from 1987 onwards,
estimated now to be 99% complete (Swedish National Board of
Health and Welfare, 1999).
The Swedish Medical Birth Register has recorded information
on all births since 1973, as well as background information on
the pregnancy and the mother. The registry is notiﬁed by the deliv-
ery units and the completeness of the register has been estimated to
be close to 100% (Cnattingius et al, 1990).
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The study population consisted of all Swedish women who had
given birth between 1st January, 1964 and 31st December, 1999
while living in a region covered by the Swedish In-patient Register.
Potential cases were identiﬁed through a linkage between the
Swedish Cancer Registry and the Swedish Registry of Births and
included all women who had given birth between 1st January,
1964 and 31st December, 1999, and had a subsequent diagnosis
of primary breast cancer through 31st December, 1999. This
resulted in data on 30419 women.
Four controls per case were initially selected and individually
matched to cases on year of birth. Controls were randomly selected
from the Swedish Registry of Births and included women who had
given birth in Sweden during the study period. Controls were eligi-
ble if they were alive, had not emigrated, and did not have a
diagnosis of breast cancer by the date of diagnosis of the case.
Data on diagnoses of hyperemesis as well as a number of
confounding variables were matched to cases and controls from
the Swedish In-patient Register and the Swedish Medical Birth
Register for all pregnancies covered by the two registries. To
increase precision, we excluded cases and controls who had not
been resident in a region covered by the Swedish In-patient Regis-
ter during any pregnancy. Due to the matched design also the
corresponding controls to excluded cases were excluded. This left
us with data on 13079 cases and 34348 matched controls, a total
of 47429 women.
Statistical methods
Relative risks were estimated by calculation of odds ratios (OR)
with 95% conﬁdence intervals (95% CI) using conditional logistic
regression for matched case–control studies.
To evaluate differences in effect on pre- and post-menopausal
breast cancer, we made sub-set analyses of cases with an age at
diagnosis of above and below 50 years. To reveal potential long-
term effects of hyperemesis we also made subset analyses by time
since hyperemesis.
Height was evaluated as a potential confounder in a subset
analysis consisting of all risk-sets where height was available for
the case and at least one control (2878 cases with a total of 7137
controls).
RESULTS
Mean age at diagnosis of breast cancer was 45 years. Of the cases,
67% were below 50 years of age at diagnosis and were in the analy-
sis considered as pre-menopausal. Compared with controls, cases
had on average fewer births, a higher age at ﬁrst birth, and were
taller. There were no differences in offspring gender or proportion
of multiple births among cases and controls. The characteristics of
cases and controls are shown in Table 1.
A diagnosis of hyperemesis during at least one pregnancy was
reported for 148 cases and 405 controls, resulting in an odds ratio
of 1.05 (95% CI 0.86–1.27) after adjustment for parity, age at ﬁrst
birth and the number of pregnancies within a region covered by
the in-patient registry (Table 2). Further adjustments for offspring
gender and multiple births did not alter the estimates. Height was
in the subset analysis not found to inﬂuence the risk estimate (data
available on request). A history of hyperemesis was not associated
with breast cancer below 50 years of age (adjusted OR=1.01), but
at 50 years of age or later this was slightly higher, OR=1.22,
although not signiﬁcantly increased (95% CI 0.79–1.88).
There was no trend in breast cancer risk with number of preg-
nancies with hyperemesis. Equally, no trend in risk was observed
depending on time between hyperemesis and diagnosis of breast
cancer (Table 3).
DISCUSSION
We found no altered risk of breast cancer following one or more
diagnoses of hyperemesis. The lack of association was independent
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Table 1 Characteristics of the 13.079 breast cancer cases and their
34.348 corresponding controls
Cases Controls P
a
Number of childbirths (mean) 2.05 2.16 0.0001
Age at ﬁrst birth (mean) 26.8 25.6 0.0001
Offspringer gender (male/female ratio) 1.06 1.06 0.86
Height (mean
b) 166.8 165.9 0.0001
Multiple births (proportion of subjects with at 0.019 0.019 0.6
least one multiple birth)
aP under null hypothesis of no difference between cases and controls.
bAmong non-
missing; missing=70%.
Table 2 Odds ratios of breast cancer in women with and without hyper-
emesis
Number Number Crude odds Adjusted
a odds
Hyperemesis of cases of controls ratio (95% CI) ratio (95% CI)
All women
No 12931 33943 1
b 1
b
Yes 148 405 1.04 1.05
(0.85–1.26) (0.86–1.27)
Women 550 years of age at diagnosis of breast cancer
No 9306 26756 1
b 1
b
Yes 112 348 1.00 1.01
(0.80–1.24) (0.81–1.26)
Women 550 years of age at diagnosis of breast cancer
No 3625 7187 1
b 1
b
Yes 36 57 1.00 1.22
(0.79–1.88) (0.79–1.88)
aAdjusted for parity, age at ﬁrst birth and number of pregnancies for which exposure
information was available.
bReference category.
Table 3 Odds ratios of breast cancer in women in hyperemesis
Number Number Crude odds Adjusted
a odds
Hyperemesis of cases of controls ratio (95% CI) ratio (95% CI)
By number of pregnancies with a report of hyperemesis
0 12.931 33.943 1
b 1
b
1 133 354 1.05 1.06
(0.86–1.29) (0.86–1.30)
2 11 37 0.93 0.96
(0.47–1.83) (0.49–1.91)
53 4 14 0.91 0.98
(0.30–2.82) (0.32–3.03)
By time between ﬁrst diagnosis of hyperemesis and diagnosis of breast cancer
c
510 years 42 107 1.28 1.21
(0.89–1.84) (0.84–1.74)
10–15 years 30 103 0.82 0.82
(0.54–1.23) (0.54–1.24)
15–20 years 33 86 1.11 1.16
(0.73–1.67) (0.77–1.76)
520 years 39 83 1.11 1.19
(0.75–1.64) (0.80–1.77)
aAdjusted for parity, age at ﬁrst birth and number of pregnancies for which exposure
information was available.
bReference category.
cOdds ratio of breast cancer for any
vs no diagnosis of hyperemesis.
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premenopausal or for postmenopausal breast cancer. A slight but
not signiﬁcantly increased risk was observed for postmenopausal
breast cancer.
At least two previous studies have examined possible associa-
tions between nausea during pregnancy and subsequent risk of
developing breast cancer. One (Troisi et al, 1998) found a
decreased risk following one or more pregnancies with self-
reported nausea, whereas the other (Enger et al, 1997) instead
observed a slight risk increase after hospital care for hyperemesis.
The reasons for the conﬂicting results are unclear. Both studies
were based on retrospective interview data, a design that is sensi-
tive to differential reporting between cases and controls. In our
study, differential misclassiﬁcation is not an issue, since informa-
tion on hyperemesis was collected from an independent source
prior to onset of disease.
Only a little more than 1% of subjects had received inpatient
care for hyperemesis. However, the study was large enough to
provide reasonably large numbers of cases and controls exposed
to hyperemesis. Levels of hCG increase with severity of nausea
(Goodwin et al, 1992), and hyperemesis requiring hospital care is
probably associated with severe nausea. Thus, our choice of hyper-
emesis as proxy variable for hCG exposure increased the difference
in exposure to hCG between exposed and non-exposed women. In
contrast, also including milder forms of nausea as exposures of
interest would have diluted the exposed population with women
suffering from nausea by non-hormonal reasons.
Parity and young age at ﬁrst birth are strong protective factors
against breast cancer (Kelsey et al, 1993). A number of possible
mechanisms have been proposed to explain this protection. Child-
bearing, especially a ﬁrst pregnancy, has been postulated to cause a
permanent modiﬁcation of the biological characteristics of the
breast. Following a pregnancy, breast epithelial cells differentiate,
a process that makes them more resistant to neoplastic transforma-
tion (Russo et al, 1982). The risk of malignant change may also be
reduced through a slowing down in the subsequent rate of cell
proliferation, and possibly also by a decrease in the carcinogen-
binding capacity (Russo and Russo, 1994). It remains unclear,
however, if these mechanisms can fully account for the lowered
breast cancer risk imparted by a pregnancy. Furthermore, the
hormones responsible for the postulated mechanisms are not yet
identiﬁed (Kelsey et al, 1993).
Our results suggest that pregnancies do not protect against
breast cancer through hCG, at least not in a dose-dependent
manner. As women with hyperemesis are exposed to high levels
of hCG, they provide one of the few human populations in which
to study effects of this hormone. Apart from increases in serum
hCG, hyperemesis has also been linked to raised levels of circulat-
ing oestrogens, particularly oestradiol (Eliakim et al, 2000). Given
that oestradiol would increase breast cancer risk, this could theore-
tically conceal a true protective effect of hCG. Oestrogens in
pregnancy-like doses have, however, been shown to protect against
breast cancer in rats in a manner similar to hCG (Rajkumar et al,
2001). Thus, opposing effects on breast cancer risk by the different
hormones seem unlikely. Hyperemesis has also been linked to
reproductive history, twinning and to an altered sex ratio of the
offspring (Askling et al, 1999; Eliakim et al, 2000), all of which
could possibly affect breast cancer risk (Kelsey et al, 1993; Hsieh
et al, 1999). All these factors were accounted for in our study,
and adjustments had no marked impact on the estimates.
Only the long-term breast cancer risk is reduced by pregnancies
(Lambe et al, 1994). A transient increase in breast cancer risk after
hyperemesis would thus not rule out the possibility of a long-term
protection. However, we did not observe any decrease in risk even
in the group with more than 20 years of follow-up.
In conclusion, we found no association between hyperemesis
and subsequent breast cancer risk, and therefore no support for
a protective effect of hCG. In spite of the promising results from
animal and in vitro studies, conﬁrmation is required before hCG
can be tested as a preventive agent against breast cancer.
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